![Shirley Kleinman](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Shirley Kleinman
Career history of Shirley Kleinman
Former positions of Shirley Kleinman
Companies | Position | Start | End |
---|---|---|---|
Notal Vision Ltd.
![]() Notal Vision Ltd. Medical/Nursing ServicesHealth Services Notal Vision Ltd. develops and manufactures computerized ophthalmic diagnostic devices. It develops age-related macular degeneration (AMD) monitor for patients at risk of vision loss from the devastating effects of wet AMD. The firm provides Preferential Hyperacuity Perimetry, a technology with clinical data for monitoring patients with AMD to eye care professionals. Its products are used for the detection and characterization of central and paracentral metamorphopsia in patients as an aid in monitoring progression of disease factors causing metamorphopsia, such as choroidal neovascularization. The company was founded in 2000 by Barak Azmon and Yair Alster and is headquartered in Tel Aviv, Israel. | Director of Finance/CFO | - | 2017-07-23 |
Training of Shirley Kleinman
Tel-Aviv University | Undergraduate Degree |
Instituto de Empresa SL | Masters Business Admin |
Statistics
International
Israel | 3 |
Spain | 2 |
Operational
Director of Finance/CFO | 1 |
Undergraduate Degree | 1 |
Masters Business Admin | 1 |
Sectoral
Consumer Services | 3 |
Health Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 1 |
---|---|
Notal Vision Ltd.
![]() Notal Vision Ltd. Medical/Nursing ServicesHealth Services Notal Vision Ltd. develops and manufactures computerized ophthalmic diagnostic devices. It develops age-related macular degeneration (AMD) monitor for patients at risk of vision loss from the devastating effects of wet AMD. The firm provides Preferential Hyperacuity Perimetry, a technology with clinical data for monitoring patients with AMD to eye care professionals. Its products are used for the detection and characterization of central and paracentral metamorphopsia in patients as an aid in monitoring progression of disease factors causing metamorphopsia, such as choroidal neovascularization. The company was founded in 2000 by Barak Azmon and Yair Alster and is headquartered in Tel Aviv, Israel. | Health Services |
- Stock Market
- Insiders
- Shirley Kleinman
- Experience